Trials / Active Not Recruiting
Active Not RecruitingNCT06865898
Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 58 (actual)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Exploring Early Biomarkers of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Using Olink Proteomics
Detailed description
The rationale for this study is that, with the changing epidemiology of liver diseases, traditional diagnostic methods are no longer sufficient to meet clinical needs. Olink technology, however, offers the potential to discover novel biomarkers. By comparing the plasma proteomic profiles of patients with cirrhosis and liver failure, we aim to identify clinically significant markers. This not only has the potential to enhance early diagnostic capabilities but also provides an important basis for personalized treatment.
Conditions
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-03-01
- Completion
- 2025-03-01
- First posted
- 2025-03-10
- Last updated
- 2025-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06865898. Inclusion in this directory is not an endorsement.